128 related articles for article (PubMed ID: 6239221)
1. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
Arrago JP; Poirier O; Najean Y
Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
[TBL] [Abstract][Full Text] [Related]
2. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
[TBL] [Abstract][Full Text] [Related]
3. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
[TBL] [Abstract][Full Text] [Related]
4. Serum procollagen III peptide in chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD
Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
[TBL] [Abstract][Full Text] [Related]
5. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy.
Hasselbalch H; Junker P; Hørslev-Petersen K; Lisse I; Bentsen KD
Am J Hematol; 1990 Jan; 33(1):18-26. PubMed ID: 2293759
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).
Taube T; Franssila K; Risteli L; Risteli J; Elomaa I
Br J Haematol; 1992 Sep; 82(1):32-7. PubMed ID: 1419800
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum.
Abildgaard N; Bendix-Hansen K; Kristensen JE; Vejlgaard T; Risteli L; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Dec; 99(3):641-8. PubMed ID: 9401078
[TBL] [Abstract][Full Text] [Related]
8. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum pro-collagen III in chronic myeloproliferative disorders.
Najean Y; Legrand M; Poirier O; Senechal A; Arrago JP
Eur J Haematol; 1990 Nov; 45(5):239-43. PubMed ID: 2261948
[TBL] [Abstract][Full Text] [Related]
10. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD; Risteli L; Risteli J
Am J Hematol; 1986 Oct; 23(2):101-11. PubMed ID: 3752065
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of determining the amino terminal fragment of procollagen III in myeloproliferative disorders].
Najean Y; Poirier O; Arrago JP
Nouv Rev Fr Hematol (1978); 1987; 29(2):123-7. PubMed ID: 3615194
[TBL] [Abstract][Full Text] [Related]
12. The significance of the aminoterminal propeptide of type III procollagen in paroxysmal nocturnal haemoglobinuria and myelofibrosis.
Vellenga E; Mulder NH; van Zanten AK; Nieweg HO; Woldring MG
Eur J Nucl Med; 1983; 8(11):499-501. PubMed ID: 6653612
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
14. Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis.
Bentsen KD; Henriksen JH; Bendtsen F; Hørslev-Petersen K; Lorenzen I
Hepatology; 1990 Jun; 11(6):957-63. PubMed ID: 2365293
[TBL] [Abstract][Full Text] [Related]
15. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
16. Aminoterminal propeptide of type III procollagen: a marker of disease activity in schistosomal patients.
Fayol V; Hassanein HI; el-Badrawy N; Ville G; Hartmann DJ
Eur J Clin Chem Clin Biochem; 1991 Nov; 29(11):737-41. PubMed ID: 1782280
[TBL] [Abstract][Full Text] [Related]
17. Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum.
Puistola U; Risteli L; Risteli J; Kauppila A
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1276-81. PubMed ID: 2220941
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.
Rousseau JC; Zhu Y; Miossec P; Vignon E; Sandell LJ; Garnero P; Delmas PD
Osteoarthritis Cartilage; 2004 Jun; 12(6):440-7. PubMed ID: 15135140
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.
Shehata M; Schwarzmeier JD; Hilgarth M; Hubmann R; Duechler M; Gisslinger H
J Clin Invest; 2004 Mar; 113(5):676-85. PubMed ID: 14991065
[TBL] [Abstract][Full Text] [Related]
20. 1 alpha(OH)D3 treatment and procollagen III (PC III) studies in idiopathic myelofibrosis.
Tsatalas C; Curtoglou G; Fotopoulos D; Halkia P; Vyzantiadis AT; Sinakos Z
Haematologica; 1989; 74(6):559-62. PubMed ID: 2628238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
